Access to a medical journal answers one question: can this user read the material under the applicable terms? It does not automatically answer whether a supplier may copy it into a database, show extracts to other users or use it to train a model. Clinical AI due diligence should examine each intended use separately.
This is a practical analytical guide, not advice on a particular contract or a definitive legal opinion. The sources and public policies referenced were checked on 19 September 2026. Rights depend on the work, agreement, proposed activity and applicable jurisdiction; a product's description as educational or research-oriented does not settle those questions.
Draw the content journey
Start with an example rather than a licence label. A hypothetical platform obtains an article, stores a copy, breaks it into searchable passages, retrieves a passage in response to a question and displays part of it beside a generated answer. Later, its team considers using the article in a model-training dataset.
Those are distinct activities. Ask which are covered, for which users, in which territories and for how long. Keep internal evaluation separate from commercial deployment. Keep access by an institution's staff separate from onward provision to unaffiliated subscribers.
Do not assume that a technical transformation resolves the rights question. A searchable index, retained extract or generated display may involve different uses from reading the original. Equally, do not assume that every use necessarily requires a new licence: applicable statutory exceptions need qualified, jurisdiction-specific assessment. The task is to identify the basis, not jump to a universal conclusion.
One website can contain several rights regimes
MedlinePlus's content-use policy provides a concrete example. It distinguishes material in the public domain from content copyrighted and licensed specifically for use on MedlinePlus. Its guidance identifies categories that can be reused and explains that other material is subject to different rules.
The lesson is not that MedlinePlus is unusually restrictive. It is that a website-level assumption can be wrong at the content level. A page may contain government-authored text, a licensed illustration and a separately owned medicine monograph. Treating the entire page as one reusable object skips the very distinction the policy makes.
Record rights for the content class actually used. When attribution is required, preserve it. When only linking is permitted, do not treat the existence of a public URL as permission to reproduce the work inside another product.
Build a rights register that an engineer can use
A rights register should connect legal terms to implementation. A spreadsheet saying "publisher agreement: yes" is not enough for a team deciding what to retain or display.
| Register field | Practical question |
|---|---|
| Work and version | Which content, edition and associated assets are covered? |
| Permitted activity | Reading, indexing, retrieval, display, evaluation or training? |
| Audience and territory | Which users and locations are included? |
| Technical conditions | What may be stored, logged, cached or exported? |
| Attribution | What must accompany an extract or linked answer? |
| End of permission | What must stop, be deleted or remain retained for a justified purpose? |
This is an original operational framework, not a statement that every contract contains these exact clauses. The point is to make gaps visible before they become product behaviour.
For the hypothetical platform, an agreement could permit retrieval and short display while excluding training. The implementation should reflect that separation. A later engineering change that routes all stored documents into a training pipeline should trigger review, not rely on the original general approval.
Do not confuse lawful access with unlimited computational use
The UK Intellectual Property Office's explanation of copyright exceptions, reviewed for this article, describes a text-and-data-mining exception for non-commercial research involving lawful access, alongside other limited exceptions. That is not a blanket permission for every commercial AI workflow.
The correct conclusion is to assess the proposed activity with appropriate legal expertise. Do not export a short summary of one country's exception into a global licence strategy. Nor should an article about licensing assert that a named competitor lacks rights because its agreements are not public.
A useful supplier question is: "What evidence can you provide, under suitable confidentiality arrangements, that the intended uses of these content classes are authorised or otherwise lawfully supported?" That asks for a basis without demanding publication of every confidential commercial term.
Plan for changed or terminated rights
Content rights can change during a product's life. Build an inventory that allows the team to identify affected documents, derived indexes, displayed extracts and cached outputs. Decide how corrections and withdrawn content will be handled as well as contract termination.
An exit clause is not operationally useful if nobody can locate the relevant copies. Test whether the supplier can trace a displayed source to its underlying version and agreement. Consider what audit evidence must remain, and distinguish that from retaining content for continued product use.
For institutional buyers, ask how a loss of a major source would affect the service. Could answers become less complete? Would users be told? Would the product continue to cite material it could no longer lawfully retrieve? These are scenario questions, not allegations that any named service does so.
Where iatroX belongs in the discussion
This article is published by iatroX and includes its own source-based proposition in the same scrutiny. The iatroX methodology, checked on 19 September 2026, describes how sources support its answers. A methodology explains product design; it should not be mistaken for disclosure of every underlying content agreement.
For publishers and partners, the useful conversation concerns the precise activity, audience, attribution and evidence required. For clinicians, the immediate question remains whether the cited source actually supports the answer. Content rights and answer reliability are related governance subjects, but proof of one does not automatically establish the other.
Frequently asked questions
Does an institutional journal subscription authorise a commercial AI service to reuse the articles?
Not automatically. The subscription terms, intended activity and applicable law need to be assessed separately.
Is every page on a government health website freely reusable?
Do not assume so. MedlinePlus explicitly distinguishes public-domain material from separately licensed content.
Does a supplier's unpublished licence mean it has no rights?
No. Request appropriate evidence through due diligence rather than infer a legal breach from the absence of public contract details.
Discuss clinical content and partnership questions with iatroX Insights →